Table 5.
Cross tabulation of concordance in the 1095 subjects between GOLD classification (GOLD stages 0 to 4) and FEV1/ht2 classification for COPD severity. The table shows the number of subjects dying (nd) under follow up as a fraction of the total number N within that group (nd/N), the estimated Kaplan-Meier mean survival for that group as years in bold and the 95% confidence limits for the estimate in parenthesis. Aggregate results for each columns and row as a whole are also shown
|
Staging by FEV1/ht2 |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1(>0.5) | Stage 2 (>0.4 and ≤0.5) | Stage 3 (>0.3 and ≤0.4) | Stage 4 (≤0.3) | ||||||||||||
| GOLD 0 | 29/75 | 11.2 | (10.2–12.2) | 13/29 | 9.8 | (8.4–11.3) | 12/15 | 9.0 | (7.1–10.8) | 2/2 | 5.7 | (0.0–13.3) | 56/121 | 10.6 | (9.8–11.4) |
| GOLD 2 | 88/195 | 10.8 | (10.2–11.4) | 66/101 | 9.3 | (8.5–10.2) | 15/18 | 6.2 | (4.7–7.6) | – | – | – | 169/314 | 10.1 | (9.6–10.6) |
| GOLD 3 | 17/37 | 10.7 | (9.6–11.9) | 101/150 | 8.7 | (8.0–9.4) | 194/253 | 7.9 | (7.4–8.4) | 76/85 | 6.1 | (5.2–6.9) | 388/525 | 8.0 | (7.7–8.4) |
| GOLD 4 | 1/1 | – | – | – | – | – | 11/13 | 6.6 | (4.3–8.9) | 98/112 | 5.8 | (5.1–6.5) | 110/126 | 6.0 | (5.2–6.7) |
| 135/308 | 11.0 | (10.5–11.4) | 180/280 | 9.1 | (8.6–9.7) | 232/299 | 7.8 | (7.4–8.3) | 176/199 | 5.9 | (5.4–6.5) | ||||